Home / Andrew Mooney
Andrew Mooney
As Director of Professional Relations, Andrew is responsible for leading Thrombolex into U.S. commercialization. Andrew is charged with achieving sales and profitability goals, and directing field organization.
Andrew works with key opinion leaders in the industry and interventionalist physicians across the US to develop awareness of Thrombolex products. He also provides technical expertise to physicians and support staff for the recommended use of the Thrombolex products. He brings over 25 years’ experience with cardiovascular companies, leading the commercialization of innovative cardiovascular technologies that are now mainstream. These include VasoSeal, the first vascular closure device, carotid stent systems, and Vascular re-entry technologies.
Prior to Thrombolex, Andrew spent 13 years at EKOS/BTG leading the US commercialization of the first FDA cleared technology to treat Pulmonary Embolism.
Andrew received his BA (HONS) degree in Nursing Studies from Sheffield Hallam University, England.
New Approach
“Thrombolex gives us the unique opportunity to bring an entirely new approach to the treatment of VTE as well as raise awareness of this condition in the public domain."
Available Now:
The BASHIR™ Endovascular Catheter is a device intended for the localized infusion of physician specified fluids, including thrombolytics, into the peripheral vasculature.
The BASHIR™ N-X Endovascular Catheter is a device intended for the localized infusion of physician specified fluids, into the peripheral vasculature, including the pulmonary arteries.
Need more details? Contact us.
We are here to assist. Contact us by phone, email or via our social media channels.